Trials / Active Not Recruiting
Active Not RecruitingNCT06957327
A Study of ERAS-601 in People With Chordoma
A Phase 1b/2 Study of ERAS-601 SHP2 Inhibitor as a Monotherapy in Patients With Advanced and Progressing Chordoma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERAS-601 | ERAS-601 40mg BID, 3-weeks on 1-week off (3/1), as monotherapy |
Timeline
- Start date
- 2025-04-25
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2025-05-04
- Last updated
- 2026-04-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06957327. Inclusion in this directory is not an endorsement.